Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

NCT03977155 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

133

Enrollment

INDUSTRY

Sponsor class

Conditions

Diarrhea-predominant Irritable Bowel Syndrome

Interventions

DRUG: BOS-589
DRUG: Placebo

Sponsor

Boston Pharmaceuticals